Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.659 CHF
−51.60 M CHF
611.61 M CHF
165.12 M
About ACADIA Pharmaceuticals Inc.
Sector
CEO
Catherine E. Owen
Headquarters
San Diego
Website
Founded
1993
FIGI
BBG00LVD4F39
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DR6 is 16.713 CHF — it has increased by 27.68% in the past 24 hours. Watch ACADIA PHARMACEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ACADIA PHARMACEUT stocks are traded under the ticker DR6.
DR6 stock hasn't changed in a week, the last month showed zero change in price, over the last year ACADIA PHARMACEUT has showed a −34.66% decrease.
We've gathered analysts' opinions on ACADIA PHARMACEUT future price: according to them, DR6 price has a max estimate of 34.73 CHF and a min estimate of 9.80 CHF. Watch DR6 chart and read a more detailed ACADIA PHARMACEUT stock forecast: see what analysts think of ACADIA PHARMACEUT and suggest that you do with its stocks.
DR6 stock is 21.68% volatile and has beta coefficient of 1.36. Track ACADIA PHARMACEUT stock price on the chart and check out the list of the most volatile stocks — is ACADIA PHARMACEUT there?
Today ACADIA PHARMACEUT has the market capitalization of 2.52 B, it has increased by 2.52% over the last week.
Yes, you can track ACADIA PHARMACEUT financials in yearly and quarterly reports right on TradingView.
ACADIA PHARMACEUT is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
DR6 earnings for the last quarter are 0.17 CHF per share, whereas the estimation was 0.12 CHF resulting in a 44.84% surprise. The estimated earnings for the next quarter are 0.19 CHF per share. See more details about ACADIA PHARMACEUT earnings.
ACADIA PHARMACEUT revenue for the last quarter amounts to 212.20 M CHF, despite the estimated figure of 210.87 M CHF. In the next quarter, revenue is expected to reach 245.90 M CHF.
DR6 net income for the last quarter is 27.77 M CHF, while the quarter before that showed 30.02 M CHF of net income which accounts for −7.50% change. Track more ACADIA PHARMACEUT financial stats to get the full picture.
No, DR6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 598.00 employees. See our rating of the largest employees — is ACADIA PHARMACEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ACADIA PHARMACEUT EBITDA is 105.54 M CHF, and current EBITDA margin is −9.34%. See more stats in ACADIA PHARMACEUT financial statements.
Like other stocks, DR6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ACADIA PHARMACEUT stock right from TradingView charts — choose your broker and connect to your account.